Investors of Mereo BioPharma Group PLC Urged to Participate in Class Action Lawsuit

Investors Urged to Join Class Action Against Mereo BioPharma

Investors holding shares of Mereo BioPharma Group PLC (NASDAQ: MREO) are being called to action as Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a class action lawsuit against the biopharmaceutical company. This legal action aims to represent individuals and entities that acquired Mereo's American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025.

Background of the Lawsuit

The lawsuit alleges that Mereo BioPharma and certain executives misled investors about their clinical trials for setrusumab, a treatment designed to combat Osteogenesis Imperfecta (OI). The claims suggest that the company repeatedly assured stakeholders that the Phase 3 clinical trials, known as ORBIT and COSMIC, would achieve significant milestones, including a statistically significant reduction in annualized fracture rates (AFR) in patients. These projections led many investors to believe in Mereo’s promise for future success.

However, the complaint points out that Mereo concealed critical information indicating that neither trial was likely to achieve its primary goals. Ultimately, both ORBIT and COSMIC failed to show any significant improvement in fracture reduction compared to control groups.

Major Developments and Shareholder Impact

On December 29, 2025, the reality struck when Mereo disclosed that neither trial met its expected endpoint. The press release revealed failures in both studies, leading to a drastic stock price drop from $2.31 to a staggering $0.29 in just one day—a decline exceeding 87% in shareholder value. This disclosure has prompted concerned investors to act quickly.

Call to Action for Affected Investors

Investors who suffered losses as a result of these events have a critical opportunity. Wolf Haldenstein is encouraging anyone affected to reach out by April 6, 2026, if they wish to be appointed as lead plaintiff in this class action. This is an essential step for those seeking redress for their financial losses.

Why Choose Wolf Haldenstein?

Established in 1888, Wolf Haldenstein is renowned for its dedication to safeguarding investor rights. With over 125 years of experience in securities litigation, the firm demonstrates a consistent commitment to defending those who have suffered from corporate misrepresentation or fraud. Legal experts at the firm are poised to take these cases forward, aiming to recover funds for investors misled by Mereo’s actions.

How to Join the Lawsuit

For those interested in joining the class action or seeking more information, it's advised to contact Wolf Haldenstein directly. Investors can reach the firm at:

- Phone: (800) 575-0735 or (212) 545-4774
- Email: [email protected]

Also, potential plaintiffs can submit their contact information online to ensure they receive necessary updates about the progress of the lawsuit.

In conclusion, this class action represents an essential pathway for investors to reclaim their losses following the tragic events that unfolded with Mereo BioPharma. Engaging the expertise of a dedicated law firm like Wolf Haldenstein may prove crucial in this endeavor for justice.